



Certificate of Participation 20XX

This is to certify that
ACME Laboratory

Participated in 2023 in the following EMQN CIC external quality assessment schemes:

Scheme	Genotyping	Interpretation	Clerical	Result
COLORECTAL CANCER	2.00	2.00	2.00	Satisfactory
DNA SEQUENCING - SANGER	2.00	1.83		Satisfactory
HBOC (BRCA1/BRCA2 testing only)	2.00	0.50	2.00	Poor
LUNG CANCER (NSCLC) [Tissue] – COMMON BIOMARKERS	2.00	2.00	2.00	Satisfactory
LUNG CANCER (NSCLC) [Tissue] – NEW and EMERGING BIOMARKERS	2.00	2.00	2.00	Satisfactory
LYNCH	2.00	1.27	1.83	Poor
ONCOGENE PANEL	2.00			Satisfactory
PIK3CA	2.00	2.00	2.00	Satisfactory
Polyposis Syndromes (FAP, MAP)	2.00	2.00	2.00	Satisfactory

The laboratory participated in 9 schemes and passed 7 of them. The detailed performance data are given on the Individual Laboratory Report (ILR). When viewing the certificates, you should ensure that 9 schemes are listed.

Key:

> Scheme Mean

< Scheme Mean

Poor performance

NRS: No Results Submitted **WFS:** Withdrew From Scheme

Signed by:



Prof. David Barton
Chair of SSAB



Dr. Simon Patton
Managing Director